Literature DB >> 29477359

Contribution of membrane receptor signalling to chronic visceral pain.

Mahsa Sadeghi1, Andelain Erickson2, Joel Castro2, Annemie Deiteren2, Andrea M Harrington2, Luke Grundy2, David J Adams1, Stuart M Brierley3.   

Abstract

Irritable bowel syndrome and inflammatory bowel disease are major forms of chronic visceral pain, which affect over 15% of the global population. In order to identify new therapies, it is important to understand the underlying causes of chronic visceral pain. This review provides recent evidence demonstrating that inflammation or infection of the gastrointestinal tract triggers specific changes in the neuronal excitability of sensory pathways responsible for the transmission of nociceptive information from the periphery to the central nervous system. Specific changes in the expression and function of a variety of ion channels and receptors have been documented in inflammatory and chronic visceral pain conditions relevant to irritable bowel syndrome and inflammatory bowel disease. An increase in pro-nociceptive mechanisms enhances peripheral drive from the viscera and provides an underlying basis for enhanced nociceptive signalling during chronic visceral pain states. Recent evidence also highlights increases in anti-nociceptive mechanisms in models of chronic visceral pain, which present novel targets for pharmacological treatment of this condition.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Afferents; Colon; Ion channels; Nociception; Pain

Mesh:

Substances:

Year:  2018        PMID: 29477359     DOI: 10.1016/j.biocel.2018.02.017

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  7 in total

Review 1.  Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome.

Authors:  Stuart M Brierley; Beverley Greenwood-Van Meerveld; Giovanni Sarnelli; Keith A Sharkey; Martin Storr; Jan Tack
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-09-27       Impact factor: 73.082

2.  Inflammation-mediated macrophage polarization induces TRPV1/TRPA1 heteromers in endometriosis.

Authors:  Hai Zhu; Yi Wang; Yibo He; Weifeng Yu
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

3.  Activation of pruritogenic TGR5, MrgprA3, and MrgprC11 on colon-innervating afferents induces visceral hypersensitivity.

Authors:  Joel Castro; Andrea M Harrington; TinaMarie Lieu; Sonia Garcia-Caraballo; Jessica Maddern; Gudrun Schober; Tracey O'Donnell; Luke Grundy; Amanda L Lumsden; Paul Miller; Andre Ghetti; Martin S Steinhoff; Daniel P Poole; Xinzhong Dong; Lin Chang; Nigel W Bunnett; Stuart M Brierley
Journal:  JCI Insight       Date:  2019-10-17

4.  Identification of potential biomarkers for abdominal pain in IBS patients by bioinformatics approach.

Authors:  Zhongyuan Lin; Yimin Wang; Shiqing Lin; Decheng Liu; Guohui Mo; Hui Zhang; Yunling Dou
Journal:  BMC Gastroenterol       Date:  2021-02-02       Impact factor: 3.067

Review 5.  Pathophysiologic Approach to Pain Therapy for Complex Pain Entities: A Narrative Review.

Authors:  Martina Rekatsina; Antonella Paladini; Alba Piroli; Panagiotis Zis; Joseph V Pergolizzi; Giustino Varrassi
Journal:  Pain Ther       Date:  2020-01-04

6.  Experimentally Induced Bladder Permeability Evokes Bladder Afferent Hypersensitivity in the Absence of Inflammation.

Authors:  Luke Grundy; Ashlee Caldwell; Amanda Lumsden; Ehsan Mohammadi; Gerhard Hannig; Beverley Greenwood Van-Meervald; Stuart M Brierley
Journal:  Front Neurosci       Date:  2020-10-23       Impact factor: 4.677

7.  Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents.

Authors:  Joel Castro; Sonia Garcia-Caraballo; Jessica Maddern; Gudrun Schober; Amanda Lumsden; Andrea Harrington; Shirdi Schmiel; Beatriz Lindstrom; John Adams; Stuart M Brierley
Journal:  Pain       Date:  2022-01-01       Impact factor: 6.961

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.